WST|Analyst Targets
WST|Company Info
WST|Insider Trading
WST|Fundamentals
WST|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $2.31 | - | - |
| Q3'26 | $2.21 | $2.66 | +20.2% |
| Q1'26 | $2.05 | $2.13 | +3.8% |
| Q4'25 | $1.67 | $2.04 | +22.1% |
| Q3'25 | $1.71 | $1.96 | +14.6% |
| Q2'25 | $1.54 | $1.84 | +19.7% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $834M | - | - |
| Q3'26 | $834M | $875M | +4.9% |
| Q1'26 | $835M | $845M | +1.2% |
| Q4'25 | $773M | $805M | +4.1% |
| Q3'25 | - | $805M | - |
| Q2'25 | - | $767M | - |
WST|Monthly Returns
Market Data
WST Stock Snapshot
- Market cap
- 29.02B
- P/E ratio
- 51.4
- Day range
- $385.32 – $402.40
- News sentiment
- 60/100 · Bullish
- Analyst target
- $471.00 (+17.8%)
- Consensus
- Buy · 23 analysts
WST is trading with the trend behind it, which is what pushes the technical read bullish. In Healthcare, names this size usually take direction from sector flows before company-level news.
Reverse DCF
What growth is priced into WST?
At today's price, West Pharmaceutical Services, Inc. needs to grow free cash flow about 26.8% a year for 3 years, slowing to a long-run rate by year 10, to justify its valuation at a 7.79% cost of capital. Over the last five years its revenue has trended at 1.7% a year, so the market is asking for 25.1 percentage points above its own delivered rate. On that basis WST looks priced above what its own growth record supports.
- Implied FCF growth
- 26.8%
- Growth trend
- 1.7%
- Growth gap
- +25.1 pts
- Verdict
- RICH
- Discount rate (WACC)
- 7.79%
- Beta
- 0.71
Behaviour On Record
What WST's own history says about today's numbers
- Realized volatility (21d)
- 23.2% 45th pct
- Below its peak
- -15.2%
- vs 200-day average
- +26.4%
- Up days (1y)
- 55%
West Pharmaceutical Services, Inc. is currently running 23.2% annualised volatility over the last 21 sessions. Measured against WST's own 13 years of daily returns rather than a market-wide average, that is the 45th percentile — close to its own typical level, against a typical reading of 24.4%.
WST is trading -15.2% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -22.8%, and the deepest was -53.0% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +26.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 91st percentile — a wider gap than this stock usually carries. Over the past year WST closed higher on 55% of sessions, and it is currently 1 session into a rising streak.
On November specifically: over 13 years of records, WST finished the month higher 10 of 13 times, with a median return of +3.0% and an average of +3.4%. Its strongest month historically has been June at +4.6% on average, its weakest February at -2.1%.
Overnight risk is measurable too: WST has opened more than 2% away from the prior close in 91 of 3,267 sessions (2.8% of the time), with the largest gaps running +9.1% and -15.7%.
Across the last 3 dated reports on file, WST moved an average of 1.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.0% and a largest of +2.8%.
All figures computed from 3,268 daily closes between 2013-11-08 and 2026-11-06, split-adjusted, recomputed daily. Percentiles are against WST's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of WST's sector?
West Pharmaceutical Services, Inc. sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening).
- Sector rank
- #1 of 12
- Sector state
- Weakening
- Sector rotation score
- 91
Analyst Consensus Estimates
What do analysts expect WST to earn?
Analysts expect West Pharmaceutical Services, Inc. to earn $9.49 per share in the fiscal year ending Dec 2026 and $11.32 in the fiscal year ending Dec 2028, from 4 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.
Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.
Analyst Rating Changes
Are analysts turning bullish or bearish on WST?
Citigroup most recently reiterated its rating on West Pharmaceutical Services, Inc. to Buy on Oct 30, 2026 with a price target of $494 (from $412). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- Citigroup: Buy
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
Earnings Release, Scored
What did West Pharmaceutical Services, Inc.'s latest earnings release say?
Most important lines
- 1
The Company repurchased $231 million of stock in the quarter, bringing the year-to-date total to $685 million.
New this quarter - 2
Net sales of $145.7 million decreased by 7.3% and declined 6.6% on an organic basis.
New this quarterNegative tone - 3
The Company also announced on October 19, 2026, that its Board of Directors declared a fourth-quarter dividend of $0.26 per share, an increase of 18% over the $0.22 per share paid in the prior quarter.
New this quarter
Peers & ETF holders
WST peers & ETF holders
Medical Instruments & SuppliesMarket cap · today
News & sentiment
What is the news saying about WST?
WST rose 7.4% over the month to Nov 6. News tone held between 53 and 100 from Oct 6 to Oct 15, then dropped to 42 on Oct 19.
- Oct 15 +2.2%same day: West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?
- Oct 29 +3.2%same day: West (WST) Stock Could Be 28% Overvalued As Cash Flow Falls Short
- Nov 5 -4.0%same day: West Pharmaceutical Services (WST) is a Great Momentum Stock: Should You Buy?
Technical analysis
How strong is WST's momentum right now?
On the daily chart WST ranks at the 75th percentile for momentum against 1,060 stocks and ETFs, a bullish reading.
Institutional ownership
Are big funds buying or selling WST?
92 of the 196 tracked managers added to WST in their latest 13F and 101 trimmed. Together they own 79.8% of the company, worth $20.4B. BlackRock and Vanguard Capital Management alone hold 15.5%.
- 1BlackRock, Inc.9.17%$2.4B positionTrimmed 2.7% last quarter
- $1.7B positionTrimmed 1.5% last quarter
- $1.4B positionTrimmed 1.9% last quarter
- 4FMR LLC (Fidelity)4.93%$1.3B positionAdded 186.0% last quarter
- 5State Street Corp4.61%$1.2B positionAdded 1.7% last quarter
- $865.8M positionTrimmed 9.3% last quarter
- $715.2M positionAdded 1.7% last quarter
- $644.7M positionTrimmed 14.9% last quarter
- 9Morgan Stanley2.18%$568.1M positionAdded 8.5% last quarter
- 10Aberdeen Group plc2.01%$71.0M positionAdded 1.4M shares last quarter
Congressional trading
Is Congress trading WST?
5 members of Congress disclosed 8 WST trades between Feb 13, 2015 and Jul 22, 2025: 3 buys and 5 sells, about $64.0K in estimated value.
What stands out
Click one to highlight its trades in the chartDiscover more
How has WST done against its peers?
Over the six months to Nov 6, WST returned +27.9%. Of the 15 related stocks and ETFs, 4 did better, led by BDX at +44.6%.
- 1BDXBecton, Dickinson and Companyup 44.6%+16.7 pts
- 2GEHCGE HealthCare Technologies Inc.up 33.5%+5.5 pts
- 3DXCMDexCom, Inc.up 31.6%+3.6 pts
- 4MDTMedtronic plcup 30.6%+2.7 pts
- 5WSTThis stockup 27.9%
- 6XLVHealth Care Select Sector SPDR Fundup 27.3%−0.6 pts
- 7ZBHZimmer Biomet Holdings, Inc.up 25.0%−2.9 pts
- 8EWEdwards Lifesciences Corporationup 22.1%−5.8 pts
- 16BSXBoston Scientific Corporationdown 23.7%−51.6 pts